NCT06494501View on ClinicalTrials.gov

The Prevent Coronary Artery Disease Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

June 30, 2032

Study Completion Date

June 30, 2032

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Inclisiran

Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.

Trial Locations (1)

10029

RECRUITING

Mount Sinai Fuster Heart Hospital, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER